Ubretid
Ubretid is a potent inhibitor of plasma cholinesterase. Ubretid therefore delays the hydrolysis of suxamethonium and prolongs its action, similar to the effects shown by other anticholinesterase agents, such as pyridostigmine and donepezil. Ubretid has the potential for the research of urinary retention prolongs the effect of suxamethonium. Ubretid is commonly prescribed for the research of myasthenia gravis and for difficulty in emptying the bladder[1].
Product Specifications
CAS Number
15876-67-2
Product Name Alternative
Distigmine (dibromide)
UNSPSC
12352005
Hazard Statement
H300, H412
Target
Cholinesterase (ChE)
Type
Reference compound
Related Pathways
Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/ubretid.html
Purity
99.0
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(N(C)CCCCCCN(C)C(OC1=C[N+](C)=CC=C1)=O)OC2=C[N+](C)=CC=C2.[Br-].[Br-]
Molecular Formula
C22H32Br2N4O4
Molecular Weight
576.32
Precautions
H300, H412
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
AChE; BChE
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Rickettsia akari D-alanine--D-alanine ligase (ddl)
Recombinant Rickettsia akari D-alanine--D-alanine ligase (ddl)
Recombinant Rickettsia akari D-alanine--D-alanine ligase (ddl)
Recombinant Rickettsia akari D-alanine--D-alanine ligase (ddl)
Recombinant Rickettsia akari D-alanine--D-alanine ligase (ddl)